Sorrento Therapeutics (SRNE) 10.36 $SRNE
Sorrento Therapeutics Announces Three Preclinical Poster Presentations on Cynviloq(TM), its Novel Antibody Drug Conjugate Linker Technology and c-Met/EGFR Bispecific ADC at the 106th Annual Meeting of the American Association for Cancer Research
PR Newswire - Sat Apr 18, 3:32PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that three preclinical abstracts are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Data to be presented include studies on the significant reduction in tumor burden and enhanced survival following Cynviloq intraperitoneal therapy, compared to albumin-bound paclitaxel* intravenous therapy in a metastatic model of ovarian cancer, successful development of anti-cancer antibody drug conjugates using novel C- and K-lock linker technology, and significant efficacy of its c-Met/EGFR Bispecific Targeting ADC in a non-small cell lung cancer model.
SRNE: 10.36 (-0.43)
Sorrento to Present at Jefferies 2015 Immuno-Oncology Summit
PR Newswire - Mon Apr 13, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at the Jefferies 2015 Immuno-Oncology Summit on Wednesday, Apr. 15 from 10:30 to 10:50 AM in the John Foster Salon at the Boston Harbor Hotel, Boston.
SRNE: 10.36 (-0.43)
Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 31, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RESN: 3.77 (-0.06), IMDZ: 26.66 (+0.22), ARCW: 7.06 (-0.57), PRQR: 18.79 (+0.64), STRA: 54.15 (+0.21), RDI: 13.82 (+0.28), CLDN: 13.59 (-2.77), SYUT: 7.61 (-0.01), CBMG: 32.14 (+2.21), SRNE: 10.36 (-0.43), PFIN: 6.40 (+0.05), RDIB: 13.04 (-0.36)
Cancer PD-1 inhibitor market only half as large as consensus says analyst
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:37AM CDT
MDVN: 128.88 (+0.29), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), BMY: 66.60 (-0.21), SRNE: 10.36 (-0.43), CELG: 115.54 (+0.72), FPRX: 24.07 (-0.85)
Strong On High Relative Volume: Sorrento Therapeutics (SRNE)
at The Street - Tue Mar 31, 9:09AM CDT
Trade-Ideas LLC identified Sorrento Therapeutics (SRNE) as a strong on high relative volume candidate
SRNE: 10.36 (-0.43)
Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer
PR Newswire - Mon Mar 30, 8:00AM CDT
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today the appointment of George K. Ng to the position of Executive Vice President & Chief Legal Officer. In this capacity, Mr. Ng will be responsible for all legal, compliance and intellectual property functions.
SRNE: 10.36 (-0.43)
Sorrento Therapeutics inks second collaboration deal with Nantworks
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 3:04PM CDT
SRNE: 10.36 (-0.43)
NantWorks And Sorrento Announce Second Comprehensive Global Collaboration On Discovery And Development Of Novel Anti-Cancer Immunotherapies
PR Newswire Europe - Mon Mar 16, 8:01AM CDT
- NantCell To Acquire Exclusive Rights to Antibodies Including CAR-TNK(TM) Products and the Checkpoint Inhibitors PD-1 and PD-L1
SRNE: 10.36 (-0.43)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 3.13 (-0.07), GLMD: 10.00 (-0.12), PTBI: 3.37 (+0.20), CNAT: 6.31 (-0.15), GALT: 3.29 (+0.01), SRNE: 10.36 (-0.43), CELG: 115.54 (+0.72), GILD: 104.18 (-1.02), KITE: 57.56 (-1.43), CFRX: 5.40 (-0.04), ICPT: 280.45 (-8.26), JUNO: 55.72 (-0.68), CORT: 6.44 (+0.38)
Sorrento to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Thu Feb 05, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at an upcoming healthcare conference.
SRNE: 10.36 (-0.43)
Sorrento Announces Retention of Glen Sato to Provide Strategic Support
PR Newswire - Mon Feb 02, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that Glen Sato, former Chief Financial Officer at PDL Biopharma, Inc. and Exelixis, Inc., and partner at Cooley LLC, has been retained to provide support for the ongoing strategic financial and legal initiatives in the business and operations of the Company.
SRNE: 10.36 (-0.43)
Sorrento Announces Completion of Enrollment in the Cynviloq(TM) Registrational TRIBECA(TM) Study
PR Newswire Europe - Wed Jan 28, 8:02AM CST
Sorrento Therapeutics, Inc. , an oncology company developing new treatments for cancer and associated pain, announced today that the last patient in (total n = 111 patients) has been randomized in the ongoing TRIBECA(TM) (TRIal establishing bioequivalence [BE] between Cynviloq(TM) and Albumin-bound paclitaxel*) registrational trial. Patients were enrolled globally from sites in USA, Eastern Europe, and Asia. The ongoing safety assessment from treated patients continues to reveal no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel. Previously, Sorrento announced positive pharmacokinetic (PK) data from the first eight (
patients enrolled in the TRIBECA study.
SRNE: 10.36 (-0.43)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 11:45AM CST
DRD: 1.85 (-0.09), OCN: 7.68 (+0.14), BBRY: 9.92 (-0.11), DCIX: 2.52 (+0.03), BBY: 36.18 (-0.27), RIC: 3.20 (+0.02), FISH: 22.46 (+0.26), NVGN: 7.40 (-0.30), SRNE: 10.36 (-0.43), WNS: 24.42 (-0.02), LPSN: 9.37 (+0.31), MUX: 0.96 (-0.01), ATNM: 3.01 (-0.07), PODD: 30.79 (-0.20), EDUC: 4.20 (unch), NGD: 3.25 (-0.15), PPC: 24.36 (+0.16), MOV: 30.62 (-0.18), KONE: 4.78 (-0.29), EHTH: 11.44 (+0.07)
Today's Weak On High Volume Stock: Sorrento Therapeutics (SRNE)
at The Street - Thu Jan 15, 9:02AM CST
Trade-Ideas LLC identified Sorrento Therapeutics (SRNE) as a weak on high relative volume candidate
SRNE: 10.36 (-0.43)
Sorrento Provides Status Update on the Cynviloq(TM) Registrational TRIBECA(TM) Study
PR Newswire - Mon Jan 12, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA(TM) (TRIal establishing bioequivalence [BE] between Cynviloq(TM) and Albumin-bound paclitaxel*) registrational trial have been dosed. Sorrento intends to continue enrolling all qualified patients in the current screening process and anticipates having the "last patient in" by the end of January. Patients were recruited globally from over 20 sites in USA, Eastern Europe, and Asia. The initial safety assessment from treated patients revealed no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel.
SRNE: 10.36 (-0.43)
Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong
PR Newswire - Tue Jan 06, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, announced today that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, is scheduled to present details about Conkwest's Neukoplast technology platform and the exclusive partnership among Sorrento, Conkwest and NantWorks to develop and commercialize "CAR.TNK" (Chimeric Antigen Receptor Tumor-attacking Neukoplast) Cell Lines, the next-generation "off-the-shelf" adoptive cancer immunotherapy.
SRNE: 10.36 (-0.43)
Sorrento To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco
PR Newswire - Mon Jan 05, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at two upcoming healthcare conferences.
SRNE: 10.36 (-0.43)
Sorrento Therapeutics Announces Three Preclinical Poster Presentations on Cynviloq(TM), its Novel Antibody Drug Conjugate Linker Technology and c-Met/EGFR Bispecific ADC at the 106th Annual Meeting of the American Association for Cancer Research
PR Newswire - Sat Apr 18, 3:32PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that three preclinical abstracts are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Data to be presented include studies on the significant reduction in tumor burden and enhanced survival following Cynviloq intraperitoneal therapy, compared to albumin-bound paclitaxel* intravenous therapy in a metastatic model of ovarian cancer, successful development of anti-cancer antibody drug conjugates using novel C- and K-lock linker technology, and significant efficacy of its c-Met/EGFR Bispecific Targeting ADC in a non-small cell lung cancer model.
SRNE: 10.36 (-0.43)
Sorrento to Present at Jefferies 2015 Immuno-Oncology Summit
PR Newswire - Mon Apr 13, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at the Jefferies 2015 Immuno-Oncology Summit on Wednesday, Apr. 15 from 10:30 to 10:50 AM in the John Foster Salon at the Boston Harbor Hotel, Boston.
SRNE: 10.36 (-0.43)
Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 31, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RESN: 3.77 (-0.06), IMDZ: 26.66 (+0.22), ARCW: 7.06 (-0.57), PRQR: 18.79 (+0.64), STRA: 54.15 (+0.21), RDI: 13.82 (+0.28), CLDN: 13.59 (-2.77), SYUT: 7.61 (-0.01), CBMG: 32.14 (+2.21), SRNE: 10.36 (-0.43), PFIN: 6.40 (+0.05), RDIB: 13.04 (-0.36)
Cancer PD-1 inhibitor market only half as large as consensus says analyst
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:37AM CDT
MDVN: 128.88 (+0.29), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), BMY: 66.60 (-0.21), SRNE: 10.36 (-0.43), CELG: 115.54 (+0.72), FPRX: 24.07 (-0.85)
Strong On High Relative Volume: Sorrento Therapeutics (SRNE)
at The Street - Tue Mar 31, 9:09AM CDT
Trade-Ideas LLC identified Sorrento Therapeutics (SRNE) as a strong on high relative volume candidate
SRNE: 10.36 (-0.43)
Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer
PR Newswire - Mon Mar 30, 8:00AM CDT
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today the appointment of George K. Ng to the position of Executive Vice President & Chief Legal Officer. In this capacity, Mr. Ng will be responsible for all legal, compliance and intellectual property functions.
SRNE: 10.36 (-0.43)
Sorrento Therapeutics inks second collaboration deal with Nantworks
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 3:04PM CDT
SRNE: 10.36 (-0.43)
NantWorks And Sorrento Announce Second Comprehensive Global Collaboration On Discovery And Development Of Novel Anti-Cancer Immunotherapies
PR Newswire Europe - Mon Mar 16, 8:01AM CDT
- NantCell To Acquire Exclusive Rights to Antibodies Including CAR-TNK(TM) Products and the Checkpoint Inhibitors PD-1 and PD-L1
SRNE: 10.36 (-0.43)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 3.13 (-0.07), GLMD: 10.00 (-0.12), PTBI: 3.37 (+0.20), CNAT: 6.31 (-0.15), GALT: 3.29 (+0.01), SRNE: 10.36 (-0.43), CELG: 115.54 (+0.72), GILD: 104.18 (-1.02), KITE: 57.56 (-1.43), CFRX: 5.40 (-0.04), ICPT: 280.45 (-8.26), JUNO: 55.72 (-0.68), CORT: 6.44 (+0.38)
Sorrento to Present at the 17th Annual BIO CEO & Investor Conference
PR Newswire - Thu Feb 05, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at an upcoming healthcare conference.
SRNE: 10.36 (-0.43)
Sorrento Announces Retention of Glen Sato to Provide Strategic Support
PR Newswire - Mon Feb 02, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that Glen Sato, former Chief Financial Officer at PDL Biopharma, Inc. and Exelixis, Inc., and partner at Cooley LLC, has been retained to provide support for the ongoing strategic financial and legal initiatives in the business and operations of the Company.
SRNE: 10.36 (-0.43)
Sorrento Announces Completion of Enrollment in the Cynviloq(TM) Registrational TRIBECA(TM) Study
PR Newswire Europe - Wed Jan 28, 8:02AM CST
Sorrento Therapeutics, Inc. , an oncology company developing new treatments for cancer and associated pain, announced today that the last patient in (total n = 111 patients) has been randomized in the ongoing TRIBECA(TM) (TRIal establishing bioequivalence [BE] between Cynviloq(TM) and Albumin-bound paclitaxel*) registrational trial. Patients were enrolled globally from sites in USA, Eastern Europe, and Asia. The ongoing safety assessment from treated patients continues to reveal no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel. Previously, Sorrento announced positive pharmacokinetic (PK) data from the first eight (
patients enrolled in the TRIBECA study. SRNE: 10.36 (-0.43)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 11:45AM CST
DRD: 1.85 (-0.09), OCN: 7.68 (+0.14), BBRY: 9.92 (-0.11), DCIX: 2.52 (+0.03), BBY: 36.18 (-0.27), RIC: 3.20 (+0.02), FISH: 22.46 (+0.26), NVGN: 7.40 (-0.30), SRNE: 10.36 (-0.43), WNS: 24.42 (-0.02), LPSN: 9.37 (+0.31), MUX: 0.96 (-0.01), ATNM: 3.01 (-0.07), PODD: 30.79 (-0.20), EDUC: 4.20 (unch), NGD: 3.25 (-0.15), PPC: 24.36 (+0.16), MOV: 30.62 (-0.18), KONE: 4.78 (-0.29), EHTH: 11.44 (+0.07)
Today's Weak On High Volume Stock: Sorrento Therapeutics (SRNE)
at The Street - Thu Jan 15, 9:02AM CST
Trade-Ideas LLC identified Sorrento Therapeutics (SRNE) as a weak on high relative volume candidate
SRNE: 10.36 (-0.43)
Sorrento Provides Status Update on the Cynviloq(TM) Registrational TRIBECA(TM) Study
PR Newswire - Mon Jan 12, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA(TM) (TRIal establishing bioequivalence [BE] between Cynviloq(TM) and Albumin-bound paclitaxel*) registrational trial have been dosed. Sorrento intends to continue enrolling all qualified patients in the current screening process and anticipates having the "last patient in" by the end of January. Patients were recruited globally from over 20 sites in USA, Eastern Europe, and Asia. The initial safety assessment from treated patients revealed no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel.
SRNE: 10.36 (-0.43)
Conkwest, Sorrento And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong
PR Newswire - Tue Jan 06, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, announced today that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, is scheduled to present details about Conkwest's Neukoplast technology platform and the exclusive partnership among Sorrento, Conkwest and NantWorks to develop and commercialize "CAR.TNK" (Chimeric Antigen Receptor Tumor-attacking Neukoplast) Cell Lines, the next-generation "off-the-shelf" adoptive cancer immunotherapy.
SRNE: 10.36 (-0.43)
Sorrento To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco
PR Newswire - Mon Jan 05, 8:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at two upcoming healthcare conferences.
SRNE: 10.36 (-0.43)
